IMGN - ImmunoGen: Going In The Right Direction For Ovarian Cancer Cure February, 26 2022 02:55 AM ImmunoGen Inc. Better-than-expected SORAYA results for the use of mirvetuximab against ovarian cancer. Deal with Lilly to de-risk the business. Strong cash position that can fund operations until 2024. For further details see: ImmunoGen: Going In The Right Direction For Ovarian Cancer Cure